Skip to content

Journal · Rheumatology · Updated 21 November 2026

Current Rheumatology Reports

Read Current Rheumatology Reports articles on DeepDyve. No university library needed.

Current Rheumatology Reports has published since 1999 and offers reviews of recent research across rheumatology, from Still’s disease and psoriatic arthritis to osteoarthritis, chronic musculoskeletal pain and axial spondyloarthritis. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Current Rheumatology Reports
Journal cover

Current Rheumatology Reports at a glance

Full title
Current Rheumatology Reports
Abbreviation (NLM)
Curr Rheumatol Rep
Publisher
Springer Nature
Print ISSN
1523-3774
Online ISSN (eISSN)
1534-6307
First published
1999
Subjects
Rheumatology
Access model
Hybrid (33% free to read in 2026)

Ways to access Current Rheumatology Reports

33% of the articles Current Rheumatology Reports published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 33% of Current Rheumatology Reports articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Current Rheumatology Reports. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Current Rheumatology Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Current Rheumatology Reports’ 2025 Journal Impact Factor is 4.9, and its 5-year Impact Factor is 5.7.

4.9

Journal Impact Factor (2025)

5.7

5-year Impact Factor (2025)

5 days

Median time to first decision

Source: journal metrics on the Current Rheumatology Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Current Rheumatology Reports research worth reading

Published January to August 2026. Summaries describe what the authors report.

  1. Open accessOsteoarthritis · Obesity

    Adipose–Joint Crosstalk in Obesity–Induced Osteoarthritis: Mechanisms, Biomarkers, and Translational Therapeutic Opportunities

    The authors review how dysfunctional fat depots drive obesity-induced osteoarthritis through crosstalk among adipocytes, macrophages, fibroblasts and chondrocytes, and point to GLP-1 receptor agonists, anti-adipokine agents and regenerative strategies as promising interventions.

    Hang et al. · Current Rheumatology Reports, published online August 8, 2026 · DOI 10.1007/s11926-026-01229-9

  2. LitStreamAutoinflammatory disease · Interferon

    Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives

    Ünal and colleagues review type I interferonopathies, monogenic autoinflammatory diseases caused by inappropriate type I interferon signaling, covering their genetic mechanisms, practical approaches to diagnosis, and current and emerging targeted treatments.

    Ünal et al. · Current Rheumatology Reports, published online July 4, 2026 · DOI 10.1007/s11926-026-01228-w

  3. LitStreamRheumatoid arthritis · Drug development

    Emerging Therapeutics in Rheumatoid Arthritis

    Carlson and colleagues review new treatment targets in rheumatoid arthritis, including T-cell pathways such as PD-1 and CD40-CD40L, B-cell therapies such as Bruton’s tyrosine kinase inhibitors, fibroblast-directed drugs, CAR-T cells and bispecific antibodies, noting mixed results so far.

    Carlson et al. · Current Rheumatology Reports, published online January 31, 2026 · DOI 10.1007/s11926-025-01209-5

  4. LitStreamBehçet’s syndrome · Vasculitis

    Behçet’s Syndrome

    Yazici and colleagues summarize what is known about Behçet’s syndrome and recent literature on its diagnosis and management, noting epidemiological studies suggesting it may not be as rare in some areas as thought, along with new treatments and imaging methods.

    Yazici et al. · Current Rheumatology Reports, published online March 24, 2026 · DOI 10.1007/s11926-026-01218-y

  5. LitStreamAutoinflammatory disease · Genetics

    NOD2-Related Multisystem Inflammatory Disorders and Recent Advances

    Wu and colleagues review diseases linked to variants in the NOD2 immune sensor gene, including Blau syndrome, Crohn’s disease and Yao syndrome, and describe their own large case-control study confirming the association between certain NOD2 variants and Yao syndrome.

    Wu et al. · Current Rheumatology Reports, published online February 12, 2026 · DOI 10.1007/s11926-026-01212-4

See every Current Rheumatology Reports article on DeepDyve

Questions about Current Rheumatology Reports

How can I read Current Rheumatology Reports articles without a subscription?

33% of Current Rheumatology Reports articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Rheumatology Reports articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Current Rheumatology Reports?

Current Rheumatology Reports’ NLM (PubMed) abbreviation is Curr Rheumatol Rep.

What is the ISSN of Current Rheumatology Reports?

The print ISSN is 1523-3774 and the online ISSN is 1534-6307.

What is the impact factor of Current Rheumatology Reports?

Current Rheumatology Reports’ Journal Impact Factor is 4.9 (2025), and its 5-year Impact Factor is 5.7, according to Springer Nature’s published metrics.

Is Current Rheumatology Reports open access?

Current Rheumatology Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 10 of 30 Current Rheumatology Reports articles (33%) carry a Creative Commons license, per Crossref.

Current Rheumatology Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Current Rheumatology Reports today

One month free, then less than $2 a day. Current Rheumatology Reports, plus millions of articles from thousands of journals.

Start free month

Like this: